Eli Lilly CEO John Lechleiter Rules Out Mega-merger Or Major Push Into Generics, Outlines Strategy Aimed At China's 21st Century Rise In An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly's chief executive officer, John Lechleiter, recently discussed with PharmAsia News' China bureau the Indianapolis-headquartered outfit's strategy to benefit from the rapid rise of China's economy and scientific capabilities while also spelling out that the company would not seek to engineer any mega-merger ahead. The organic chemist who heads Lilly suggested in a keynote talk in Shanghai that Chinese scientists would increasingly help shape "the century of human medicine" if the government strengthens the intellectual property regime in order to unleash innovation (PharmAsia News, April 02, 2010), and expanded on those ideas in a follow-up interview.
You may also be interested in...
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
Lilly Shifts Gears In China With New Shanghai-based R&D Center
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes